The resulting shortage impacted a wide range of medical treatments and surgical procedures that rely on plasma-derived components, including albumin and coagulation factors. This shortage highlighted the need for robust donation systems and strategic reserves to ensure the continuous supply of essential therapeutic products. As vaccination efforts progressed and the transmission of the virus was brought under control, healthcare systems across North America began returning to normalcy. This transition is expected to gradually restore the demand for plasma-derived therapies and re-establish growth trends in the market.
The COVID-19 pandemic is creating unprecedented operational and clinical challenges for healthcare institutions in the region. Moreover, the shift of priorities from chronic diseases and disorders treatments to COVID-19 diagnosis and treatment devices is leading to a decline in market growth up to a certain extent. Although no specific drug therapy for COVID-19 has been approved, convalescent plasma therapy is expected to improve the survival rate of COVID-19 patients based on the results of a number of clinical trials. For instance, in North America, the food and drug administration has approved the emergency use authorization of convalescent plasma for the treatment and care of COVID-19 patients. The EUA, i.e., emergency use authorization, has authorized the distribution of convalescent plasma in the US for treating suspected and confirmed COVID-19 patients. Thus, the emergency use of convalescent plasma for treating COVID-19 patients is leading to a positive impact on market growth.
Moreover, due to the COVID-19 outbreak, there was an overall decrease in blood donations, which ultimately affected the blood and plasma-derived products. The decreased blood donations affected the surgical procedures and treatments of other chronic diseases that require plasma-derived products or blood transfusions. Thus, the COVID-19 outbreak negatively impacted the plasma fractionation market in North America. However, with the beginning vaccination drives and the decrease in transmission rate, healthcare systems will return to normal in the long run. This, in turn, is expected to increase the demand for blood and plasma-derived products for the treatment of various disorders.
The North America Plasma Fractionation Market is witnessing robust growth due to increasing demand for plasma-derived therapies, a rising geriatric population, and the prevalence of rare and chronic diseases. Plasma fractionation refers to the process of separating plasma into its various components, such as immunoglobulins, albumin, and clotting factors, which are essential in treating a variety of medical conditions. The North America Plasma Fractionation Market is being driven by advancements in biotechnology, strong healthcare infrastructure, and the rising awareness of plasma-based therapies across the region.
One of the key factors propelling the North America Plasma Fractionation Market is the increasing incidence of immunodeficiency disorders and autoimmune diseases. With the growing number of patients requiring immunoglobulin therapies, the demand for high-quality plasma-derived products is at an all-time high. Moreover, favorable reimbursement policies and government initiatives supporting plasma donation and production are also contributing significantly to the expansion of the North America Plasma Fractionation Market.
Technological innovations in the fractionation process have made it possible to produce plasma components more efficiently and with higher purity. These advancements are enabling the North America Plasma Fractionation Market to deliver better treatment outcomes while reducing the risk of side effects. In addition, the increased focus on research and development is enhancing the therapeutic application of plasma products, further boosting the market growth.
The North America Plasma Fractionation Market is segmented based on product type, application, end-user, and country. Among product types, immunoglobulins dominate the market, given their extensive use in treating immune deficiencies and neurological conditions. The demand for albumin in liver diseases and burn treatments is also contributing to the rising market share. Hospitals and clinics are the primary end-users in the North America Plasma Fractionation Market, utilizing plasma-derived therapies for acute and chronic treatment procedures.
Geographically, the United States holds the largest share in the North America Plasma Fractionation Market owing to its advanced healthcare infrastructure, high healthcare expenditure, and presence of key industry players. The increasing number of plasma collection centers and strong regulatory support also add to the market’s strength in the region. Canada is also showing promising growth due to rising healthcare investments and enhanced access to plasma products.
The North America Plasma Fractionation Market is also witnessing a growing trend in contract manufacturing and strategic partnerships among biopharmaceutical firms. These collaborations are aimed at expanding production capacities and increasing the availability of plasma-derived therapies. Furthermore, the COVID-19 pandemic highlighted the critical role of plasma in developing treatments, which brought renewed focus and investment into the North America Plasma Fractionation Market.
In conclusion, the North America Plasma Fractionation Market is poised for continued expansion, driven by a combination of clinical needs, technological progress, and supportive regulatory environments. As the healthcare industry continues to evolve, the North America Plasma Fractionation Market will remain a cornerstone in the treatment of complex and chronic diseases, offering innovative solutions to improve patient outcomes across the continent.
𝐓𝐡𝐞 𝐋𝐢𝐬𝐭 𝐨𝐟 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬
Bharat Serums and Vaccines Limited (BSV)
Bio Products Laboratory Ltd.
CSL Limited
Grifols, S.A.
Kedrion S.p.A
Octapharma AG
SK Plasma
Market Overview and Dynamics
The plasma fractionation market in North America is expected to grow from US$ 9,484.91 million in 2021 to US$ 14,740.90 million by 2028; it is estimated to grow at a CAGR of 6.5% from 2021 to 2028. The market players associated with metabolomics are actively exploring the possible innovative technologies to facilitate researchers and medical care as the plasma containing the essential components to treat a disease, such as antibodies. Various studies are being carried out on the possible applications of plasma for illnesses that are difficult to cure by employing traditional approaches. Moreover, rising awareness about the advantages of blood donation and applications of plasma among people is expected to open new scope for the market.
Key Market Segments
North America plasma fractionation market is segmented into product, application, end user, and country. The North America plasma fractionation market, based on product, has been segmented into immunoglobulin, albumin, coagulation factor concentrates, protease inhibitors, and others. The immunoglobulin segment is likely to hold the largest share of the market in 2021. The North America plasma fractionation market, based on application is segmented into neurology, immunology, hematology, critical care, pulmonology, and others. In 2021, the Neurology segment is likely to hold the largest share of the market. The North America plasma fractionation market, based on end user is segmented into hospitals and clinics, clinical research laboratories, academic institutes. In 2021, the hospitals and clinics segment is likely to hold the largest share of the market. Based on country, the North America plasma fractionation market is segmented into the US, Canada, and Mexico. The US held the largest market share in 2020.
About Us-
Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications.
